X

XGN

XGN

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
0%Bearish
Buy/Sell Ratio0% buys
BearishBullish
XGN Live QuoteReal-time
$3.61
$3.87(-51.74%)1M
Day Range$3.48 – $3.90
Open$3.73
Previous Close$3.80
Volume508.8K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$96.95M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-0.76
Price to Book7.2
Dividend Yield0.65%
Beta (Volatility)2.24
IndustryDIAGNOSTICS & RESEARCH
52-Week RangeCurrent: $3.61 (15%)
Low: $2.59High: $9.22
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$9.43-93.7% upside

Insider Buys

0

$0

Insider Sales

1

$746K

Total Volume

$746K

1 transactions

Net Activity

$746K

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
35CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
C
1

Chernett Jorey

10%

0 buys1 sells

$746K total

Trading History
XGN insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Nov 12, 2026

1 weeks ago

Chernett Jorey

10%

10% Owner
Sell167.5K$4.45$746K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
XGN Buy Conviction0%
Industry Rank#370 of 569
Volume Contribution0.0%
Total Industry Activity$16.52B

XGN has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. XGN ranks #370 in insider activity out of 569 tracked companies in its industry.

Insider Trading Summary & Commentary
Automated executive transaction analysis for XGN

Over the last 90 days, corporate insiders at XGN (XGN) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 1 were sales. The total volume of insider trading reached $746K.

The net insider activity for XGN shows a net selling bias of $746K. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Chernett Jorey (10%), who traded 167.5K shares valued at $746K on Nov 12, 2026.

Live Market News & Developments
Aggregated real-time headlines for XGN (XGN)
6 updates

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Yahoo Finance10d ago

XGN - Exagen Inc Stock Price and Quote

Finviz176d ago

EXAGEN INC. SEC Filing (Nov 18, 2026)

Stock Titan2d ago

Exagen: Q3 Raises Questions About The Turnaround (Rating Downgrade)

Seeking Alpha7d ago

Exagen director Jorey Chernett sells $745,794 in XGN shares

Investing.com6d ago

Exagen Inc. (XGN) Stock Price & News

Syfe57d ago

FAQs About XGN Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for XGN.

Based on SEC Form 4 disclosures, the Insider Confidence Score for XGN is currently 35/100, which reflects a moderate distribution bias. This calculation accounts for a total of 0 purchases and 1 sales by company executives over the last 90 days.

The CEO Conviction Index for XGN is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.